The vascular targeting agent combretastatin-A4 and a novel cis-restricted β-lactam analogue, CA-432, induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying multidrug resistance

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 2, 2010, Pages 302-313

  Greene, Lisa M ^a   Nathwani, Seema M ^a   Bright, Sandra A ^a   Fayne, Darren ^a   Croke, Aisling ^a   Gagliardi, Maria ^a   McElligott, Anthony M ^b   O'Connor, Lisa ^d   Carr, Miriam ^a   Keely, Niall O ^a   O'Boyle, Niamh M ^a   Carroll, Peig ^b   Sarkadi, Balazs ^c   Conneally, Eibhlin ^b   Lloyd, David G ^a   Lawler, Mark ^b   Meegan, Mary J ^a   Zisterer, Daniela M ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BETA LACTAM DERIVATIVE; BUB1 RELATED PROTEIN; CA 432; COMBRETASTATIN A4; DASATINIB; DOXORUBICIN; IMATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; EX VIVO STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOLECULAR DOCKING; MULTIDRUG RESISTANCE; MYELOID LEUKEMIA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; AZETIDINES; BETA-LACTAMS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GUAIACOL; HL-60 CELLS; HUMANS; K562 CELLS; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; MICROTUBULES; MOLECULAR STRUCTURE; STEREOISOMERISM; STILBENES; TUBULIN;

EID: 78149279339     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.170415     Document Type: Article

References (40)

1. Al-alami O, Sammons J, Martin JH, and Hassan HT (1998) Divergent effect of taxol on proliferation, apoptosis and nitric oxide production in MHH225 CD34 positive and U937 CD34 negative human leukaemia cells. Leuk Res 22:939-945.
2. Alloatti D, Giannini G, Cabri W, Lustrati I, Marzi M, Ciacci A, Gallo G, Tinti MO, Marcellini M, Riccioni T, et al. (2008) Synthesis and biological activity of fluorinated combretastatin analogues. J Med Chem 51:2708-2721.
3. Alvarez C, Alvarez R, Corchete P, Pérez-Melero C, Peláez R, and Medarde M (2007) Synthesis and biological activity of naphthalene analogues of phenstatins: naphthylphenstatins. Bioorg Med Chem Lett 17:3417-3420.
4. Bellina F, Cauteruccio S, Monti S, and Rossi R (2006) Novel imidazole-based combretastatin A-4 analogues: evaluation of their in vitro antitumor activity and molecular modeling study of their binding to the colchicine site of tubulin. Bioorg Med Chem Lett 16:5757-5762.
5. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, and Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 57:1829-1834.
6. Deng X, Gao F, Flagg T, and May WS Jr (2004) Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci USA 101:153-158.
7. Forkner CE (1938) Leukemia and Allied Disorders. New York: The MacMillian Company.
8. Frankel AE and Gill PS (2004) VEGF and myeloid leukemias. Leuk Res 28:675-677.
9. Gambacorti-Passerini C, Barni R, le Coutre P, Zucchetti M, Cabrita G, Cleris L, Rossi F, Gianazza E, Brueggen J, Cozens R, et al. (2000) Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 92:1641-1650.
10. Greene LM, Campiani G, Lawler M, Williams DC, and Zisterer DM (2008) BubR1 is required for a sustained mitotic spindle checkpoint arrest in human cancer cells treated with tubulin-targeting pyrrolo-1,5-benzoxazepines. Mol Pharmacol 73: 419-430.
11. Griggs J, Metcalfe JC, and Hesketh R (2001) Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2:82-87.
12. Grzanka A, Grzanka D, Orlikowska M, Zuryn A, and Grzanka A (2005) Estimation of taxol influence on changes in tubulin and vimentin systems in K-562 and HL-60 cell lines by immunofluorescence microscopy. Neoplasma 3:193-198.
13. Hsieh HP, Liou JP, and Mahindroo N (2005) Pharmaceutical design of antimitotic agents based on combretastatins. Curr Pharm Des 11:1655-1677.
14. Kirsch DG, Doseff A, Chau BN, Lim DS, de Souza-Pinto NC, Hansford R, Kastan MB, Lazebnik YA, and Hardwick JM (1999) Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 274:21155-21161.
15. Kuwazuru Y, Yoshimura A, Hanada S, Ichikawa M, Saito T, Uozumi K, Utsunomiya A, Arima T, and Akiyama S (1990) Expression of the multidrug transporter, P-glycoprotein, in chronic myelogenous leukaemia cells in blast crisis. Br J Haematol 74:24-29.
16. Lee EA, Keutmann MK, Dowling ML, Harris E, Chan G, and Kao GD (2004) Inactivation of the mitotic checkpoint as a determinant of the efficacy of microtubule- targeted drugs in killing human cancer cells. Mol Cancer Ther 3:661-669.
17. Li W, Lan Z, Wu H, Wu S, Meadows J, Chen J, Zhu V, and Dai W (1999) BUBR1 phosphorylation is regulated during mitotic checkpoint activation. Cell Growth Differ 10:769-775.
18. Li YM and Broome JD (1999) Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 59:776-780.
19. Mateo C, Alvarez R, Pérez-Melero C, Peláez R, and Medarde M (2007) Conformationally restricted macrocyclic analogues of combretastatins. Bioorg Med Chem Lett 17:6316-6320.
20. McElligott AM, Maginn EN, Greene LM, McGuckin S, Hayat A, Browne PV, Butini S, Campiani G, Catherwood MA, Vandenberghe E, et al. (2009) The novel tubulin-targeting agent pyrrolo-1,5-benzoxazepine-15 induces apoptosis in poor prognostic subgroups of chronic lymphocytic leukemia. Cancer Res 69:8366-8375.
21. McGown AT and Fox BW (1989) Structural and biochemical comparison of the anti-mitotic agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des 3:249-254.
22. Mechetner E, Kyshtoobayeva A, Zonis S, Kim H, Stroup R, Garcia R, Parker RJ, and Fruehauf JP (1998) Levels of multidrug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 4:389-398.
23. Meraldi P, Draviam VM, and Sorger PK (2004) Timing and checkpoints in the regulation of mitotic progression. Dev Cell 7:45-60.
24. Minotti AM, Barlow SB, and Cabral F (1991) Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem 266:3987-3994.
25. Nabha SM, Mohammad RM, Dandashi MH, Coupaye-Gerard B, Aboukameel A, Pettit GR, and Al-Katib AM (2002) Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin Cancer Res 8:2735-2741.
26. Nathwani SM, Butler S, Fayne D, McGovern NN, Sarkadi B, Meegan MJ, Lloyd DG, Campiani G, Lawler M, Williams DC, et al. (2010) Novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines, induce apoptosis in multidrug-resistant cancer cells. Cancer Chemother Pharmacol 66:585-596.
27. Penzotti JE, Lamb ML, Evensen E, and Grootenhuis PD (2002) A computational ensemble pharmacophore model for identifying substrates of P-glycoprotein. J Med Chem 45:1737-1740.
28. Petit I, Karajannis MA, Vincent L, Young L, Butler J, Hooper AT, Shido K, Steller H, Chaplin DJ, Feldman E, et al. (2008) The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 111:1951-1961.
29. Pettit GR, Singh SB, Niven ML, Hamel E, and Schmidt JM (1987) Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 50:119-131.
30. Pui CH and Evans WE (1998) Acute lymphoblastic leukemia. N Engl J Med 339: 605-615.
31. Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD, and Pietenpol JA (1998) Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 273:30777-30784.
32. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, et al. (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348.
33. Soverini S, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G, Pane F, Saglio G, and Baccarani M (2004) Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 7:1205-1213.
34. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, and Longo DL (1998) Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 18:3509-3517.
35. Staud F and Pavek P (2005) Breast cancer resistance protein (BCRP/ABCG2). Int J Biochem Cell Biol 37:720-725.
36. Sudo T, Nitta M, Saya H, and Ueno NT (2004) Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res 64:2502-2508.
37. Vilpo JA, Koski T, and Vilpo LM (2000) Selective toxicity of vincristine against chronic lymphocytic leukemia cells in vitro. Eur J Haematol 65:370-378.
38. Younes A, Ayoub JP, Sarris A, Hagemeister F, North L, Pate O, McLaughlin P, Rodriguez MA, Romaguera J, Kurzrock R, et al. (1997) Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial. Br J Haematol 96:328-332. (Pubitemid 27077368)
39. Young SL and Chaplin DJ (2004) Combretastatin A4 phosphate: background and current clinical status. Expert Opin Investig Drugs 13:1171-1182.
40. Willis SG, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D, Stoffregen EP, McWeeney S, Kovacs I, Park B, et al. (2005) High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 106:2128-2137.